No efficacy data expected until 2027, limiting near-term trading catalysts. Monitor ESMO 2026 for trial-in-progress poster (October) and any early safety signals.
Price Chart
Executive Summary
Molecular Partners announced dosing of first patients in a Phase 2 proof-of-concept study (TACTIC) of MP0317 combined with chemoimmunotherapy for first-line advanced biliary tract carcinoma. The trial is recruiting 75 patients across nine sites in France, with a data update expected in 2027 and completion in 2028. This is an early-stage clinical milestone with no efficacy data yet, providing limited near-term stock catalyst.
Key Facts
- First patients dosed in investigator-initiated Phase 2 TACTIC study of MP0317 in first-line advanced biliary tract carcinoma (cholangiocarcinoma).
- Randomized, multicenter study in France targeting 75 patients (2:1 ratio, 50 experimental vs 25 control).
- Nine expert trial sites activated and patient treatment ongoing.
- Data update expected in 2027; trial completion expected in 2028.
- Trial-in-progress poster accepted for ESMO 2026 (October 23-27, Madrid).
- MP0317 is a FAP-localized CD40 agonist designed to remodel tumor microenvironment.
- Phase 1 dose-escalation study (46 patients, 9 dose levels) published in Nature Cancer showed tumor-localized CD40 activation and TME remodeling.
Financial Impact
No financial data provided; clinical-stage company with no approved products or revenue from MP0317.
Risk Factors
- Clinical trial failure or insufficient efficacy in Phase 2.
- Long timeline to data (2027) with no interim catalysts.
- Competition from existing therapies for cholangiocarcinoma.
- Cash burn without near-term revenue; reliance on financing.
- Historical poor stock performance on similar neutral events.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3328214 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 25, 2026 9w ago | 6-K | $4.38 $3.99 | ▼ −8.90% | ▼ −10.15% | $3.81 (−13.01%) |
Jul 20, 2026 14w ago | 6-K | $4.00 $4.25 | ▲ +6.25% | ▲ +2.13% | $3.81 (−4.75%) |
Jul 16, 2026 14w ago | Press Release | $4.10 $4.21 | ▲ +2.68% | ▼ −0.93% | $3.81 (−7.07%) |
Jul 6, 2026 16w ago | Press Release | $4.00 $3.93 | ▼ −1.75% | ▼ −1.18% | $3.81 (−4.75%) |
Jul 2, 2026 16w ago | 6-K | $3.98 $3.93 | ▼ −1.26% | ▼ −0.84% | $3.81 (−4.27%) |
Jul 2, 2026 16w ago | Press Release | $3.98 $3.93 | ▼ −1.26% | ▼ −0.84% | $3.81 (−4.27%) |
Jun 1, 2026 21w ago | 6-K | $3.95 $3.87 | ▼ −2.03% | ▼ −0.73% | $3.81 (−3.54%) |
May 12, 2026 24w ago | 6-K | $4.00 $3.71 | ▼ −7.25% | ▼ −6.64% | $3.81 (−4.75%) |
May 1, 2026 25w ago | Press Release | $4.24 $3.95 | ▼ −6.84% | ▼ −12.12% | $3.81 (−10.14%) |
Mar 30, 2026 30w ago | 6-K | $3.93 $4.28 | ▲ +8.91% | ▼ −3.69% | $3.81 (−3.05%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers